Vamorolone - ReveraGen Biopharma

Drug Profile

Vamorolone - ReveraGen Biopharma

Alternative Names: VB-15; VBP-15

Latest Information Update: 16 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ReveraGen BioPharma
  • Developer National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Neurological Disorders and Stroke; ReveraGen BioPharma; University of Pittsburgh
  • Class Anti-inflammatories; Antianaemics; Antiasthmatics; Corticosteroids; Glucocorticoids; Pregnatrienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy
  • Phase I Asthma; Cystic fibrosis; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Sickle cell anaemia
  • Discontinued Amyotrophic lateral sclerosis; Spinal muscular atrophy

Most Recent Events

  • 01 Nov 2017 ReveraGen BioPharma completes a phase II trial in Duchenne muscular dystrophy (In children) in Canada, USA, Australia, Israel, Sweden, United Kingdom (PO) (NCT02760264)
  • 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
  • 01 Jan 2017 ReveraGen BioPharma initiates an extension phase II trial for Duchenne muscular dystrophy (In children) in USA (PO) (NCT03038399)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top